Shares of Humana Inc. (NYSE: HUM) sold by Hennion & Walsh Asset Management Inc.

0

Hennion & Walsh Asset Management Inc. reduced its stake in the shares of Humana Inc. (NYSE: HUMGet a rating) by 11.0% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor held 2,663 shares of the insurance provider after selling 329 shares during the quarter. Hennion & Walsh Asset Management Inc.’s holdings in Humana were worth $1,159,000 at the end of the most recent reporting period.

Several other institutional investors have also recently changed their positions in HUM. Spire Wealth Management bought a new position in Humana in the fourth quarter worth about $30,000. BerganKDV Wealth Management LLC increased its holdings in Humana by 885.7% in the fourth quarter. BerganKDV Wealth Management LLC now owns 69 shares of the insurance provider valued at $32,000 after buying 62 additional shares in the last quarter. Riverview Trust Co acquired a new position in Humana in the first quarter worth approximately $32,000. Bank of New Hampshire acquired a new stake in shares of Humana in the first quarter worth approximately $36,000. Finally, PrairieView Partners LLC acquired a new stake in shares of Humana in the fourth quarter valued at approximately $44,000. 94.93% of the shares are held by institutional investors and hedge funds.

NYSE: HUM opened at $483.38 on Monday. The stock has a fifty-day moving average price of $446.81 and a two-hundred-day moving average price of $435.11. The stock has a market capitalization of $61.14 billion, a price/earnings ratio of 20.51, a PEG ratio of 1.39 and a beta of 0.80. The company has a debt ratio of 0.74, a quick ratio of 1.53 and a current ratio of 1.53. Humana Inc. has a 1-year minimum of $351.20 and a 1-year maximum of $490.11.

Human (NYSE: HUMGet a rating) last released its quarterly earnings data on Wednesday, April 27. The insurance provider reported earnings per share (EPS) of $8.04 for the quarter, beating the consensus estimate of $6.83 by $1.21. The company posted revenue of $23.97 billion in the quarter, compared to $23.54 billion expected by analysts. Humana had a return on equity of 17.27% and a net margin of 3.51%. Humana’s revenue increased by 16.0% compared to the same quarter last year. In the same quarter a year earlier, the company posted earnings per share of $7.67. On average, analysts expect Humana Inc. to post EPS of 24.65 for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, July 29. Shareholders of record on Thursday, June 30 will receive a dividend of $0.7875. This represents an annualized dividend of $3.15 and a yield of 0.65%. The ex-dividend date is Wednesday, June 29. Humana’s dividend payout ratio (DPR) is 13.36%.

Several equity research analysts have recently weighed in on HUM shares. Truist Financial raised its price target on Humana from $460.00 to $490.00 in a Thursday, April 7 report. UBS Group upgraded Humana from a “neutral” rating to a “buy” rating and raised its price target for the company from $486.00 to $520.00 in a Wednesday, April 13 report. StockNews.com upgraded Humana from a “buy” rating to a “strong buy” rating in a report on Wednesday, April 20. Loop Capital began covering Humana in a report on Thursday, June 16. They issued a “buy” rating and a price target of $510.00 for the company. Finally, Sanford C. Bernstein began covering Humana in a research note on Thursday, May 26. They set a “market performance” rating and a price target of $506.00 for the company. Five equity research analysts gave the stock a hold rating, twelve gave the company a buy rating and one gave the company’s stock a strong buy rating. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $494.33.

In related news, CAD William Kevin Fleming sold 3,210 shares in a trade on Thursday, April 28. The stock was sold at an average price of $449.68, for a total transaction of $1,443,472.80. As a result of the sale, the accounting chief now owns 884 shares of the company, valued at $397,517.12. The transaction was disclosed in a document filed with the SEC, accessible via this hyperlink. Also, insider Samir Deshpande sold 3,957 shares in a trade on Tuesday, May 3. The shares were sold at an average price of $434.19, for a total value of $1,718,089.83. Following the sale, the insider now directly owns 5,529 shares of the company, valued at approximately $2,400,636.51. Disclosure of this sale can be found here. Insiders have sold 10,644 shares of the company worth $4,702,360 in the past three months. 0.39% of the shares are held by insiders.

Humana Company Profile (Get a rating)

Humana Inc, together with its subsidiaries, operates as a health and wellness company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental insurance plans to individuals. It also has a contract with the Centers for Medicare and Medicaid Services to administer the Transitional Prescription Drug Plan program for new eligibles with limited income; and contracts with various states to provide Medicaid, dual eligibility, and long-term support services.

Featured articles

Institutional ownership by quarter for Humana (NYSE:HUM)



Get news and reviews for Humana Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Humana and related companies with MarketBeat.com’s free daily email newsletter.

Share.

Comments are closed.